Ludwig Institute for Cancer Research Limited

Memorial Sloan Kettering Cancer Center

Other

Abbott Laboratories Corporation

Cornell Research Foundation Inc.

Achim Jungbluth

Gerd J Ritter

Lloyd J Old

Elisabeth Stockert

Lloyd Old

Webster K Cavenee

Yao-tseng Chen

Matthew J Scanlan

Sydney Welt

Con Panousis

Antony Wilks Burgess

Christoph Renner

Edouard Collins Nice

Terrance Grant Johns

George Mark

Cynthia H Scanlan, Legal Representative

Anne Murray

Leonard Cohen

Andrew Mark Scott

Denise Frosina

Huei-Jen Su Huang

Nancy Kemeny

Peter Collins

Elizabeth Stockert

Terrance Grant Jonhs

Huei-Jen Huang

Anthony Wilks Burgess

An exemplary tissue array, and a method for producing the same, can be provided which can include providing an accepter biological structure(s), providing a donor tissue(s), removing a portion(s) of the donor tissue(s), and removing a portion(s) of the accepter biological structure(s). The removed portion(s) of the accepter biological structure(s) can have a size that is substantially similar to a size of the removed portion(s) of the donor tissue(s). The removed portion(s) of the donor tissue(s) can be inserted into the accepter biological structure(s) at a location substantially corresponding to the removed portion(s) of the accepter biological structure(s).

Tissue array using a carrier medium and method for providing the same

The invention relates to specific binding members, particularly antibodies and active fragments thereof, which recognize an aberrant post-translationally modified, particularly an aberrant glycosylated form of the EGFR. The binding members, particularly antibodies and fragments thereof, of the invention do not bind to EGFR on normal cells in the absence of amplification of the wild-type gene and are capable of binding the de2-7 EGFR at an epitope which is distinct from the junctional peptide. Antibodies of this type are exemplified by the novel antibody 806 whose VH and VL sequences are illustrated as SEQ ID NOs: 2 and 4 and chimeric antibodies thereof as exemplified by ch806.

Specific binding proteins and uses thereof

Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33-like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.

A34 and A33-like 3 DNA protein, antibodies thereto and methods of treatment using same

Polynucleotide molecules and polypeptide molecules A34 and A33-like 3 are described, as well as antibodies to polypeptide molecules A34 and A33like 3. Also described are methods of detecting cancers expressing these polypeptides, and methods and kits for diagnosing said cancers, and methods of inhibiting effects of a cancer in a patient.

A34 and A33-like 3 DNA, proteins, antibodies thereto and methods of treatment using same

This invention relates to a combination of immunotherapy and chemotherapy to promote tumor regression by treating a patient in need thereof with a combination of a humanized antibody that binds to A33 antigen and one or more chemotherapeutic agents. The method is useful for treating patients with colorectal cancer and gastric carcinomas. The method is particularly useful for treating patients who have tumors that are resistant to one or more chemotherapeutic agents and/or have metastasized.

Method for treating cancer using A33 specific antibodies and chemotherapeutic agents

The invention relates to monoclonal antibodies which specifically bind to the tumor rejection antigen precursor molecule Melan-A, hybridomas which produce these monoclonal antibodies, and their use. Also described is a recombinant form of Melan-A and immunogenic compositions containing the molecules, and an adjuvant.

Monoclonal antibodies which bind to tumor rejection antigen precursor

Growing community of inventors

New York, NY, United States of America

Achim Jungbluth